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Abstract 
Leukocytes respond rapidly to pathogenic and other insults with responses 
ranging from cytokine production through to migration and phagocytosis. 
These are bioenergetically expensive and increased glycolytic flux provides 
ATP rapidly to support these essential functions. However, much of this work 
is from animal studies. To better understand the relative role of glycolysis 
and oxidative phosphorylation in human leukocytes, especially their utility in 
a translational research setting, we undertook a study of human peripheral 
blood mononuclear cells (MNCs) bioenergetics. Glycolysis was essential 
during LPS-mediated IL-1β, IL-6, and TNFα production as 2-deoxy-D-
glucose significantly decreased output of all three cytokines. After optimising 
cell numbers and the concentrations of all activators and inhibitors, oxidative 
phosphorylation and glycolysis profiles of fresh and 
cryopreserved/resuscitated MNCs were determined to explore the utility of 
MNCs for determining the bioenergetics health profile in multiple clinical 
settings. While the LPS-induced cytokine response did not differ significantly 
between fresh and resuscitated cells from the same donors, 
cryopreservation/resuscitation significantly affected some measures of 
oxidative phosphorylation mostly, but also glycolysis. Bioenergetics analysis 
of human MNCs provides a quick, effective means to measure the 
bioenergetics health index of many individuals but cryopreserved cells are 
not suitable for such an analysis. The translational utility of this approach 
was tested by comparing MNCs of pregnant and non-pregnant women to 
reveal increased bioenergetics health index with pregnancy but significantly 
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reduced basal glycolysis and glycolytic capacity. More detailed analysis of 
discrete leukocyte populations would be required to understand the relative 
roles of glycolysis and oxidative phosphorylation during inflammation and 
other immune responses.  
 4 
Introduction 
Cell viability and effector functions are dependent on energy production in 
the form of adenosine triphosphate (ATP) (1). Typically, glucose is taken up 
by a cell to generate pyruvate via glycolysis; pyruvate is oxidized into acetyl-
CoA which enters the tricarboxylic acid (TCA) or Krebs cycle (1); the Krebs 
cycle yields NADH for downstream energy production via oxidative 
phosphorylation within the mitochondria (2). Glycolysis yields a net of 2 ATP 
molecules per molecule of glucose whereas oxidative phosphorylation yields 
in excess of 30 molecules of ATP per molecule of glucose (3). Other fuels 
such as fatty acids may be utilized for ATP generation. They are typically fed 
into the TCA cycle within the mitochondria via the enzyme carnitine 
palmitoyltransferase 1 (CPT1) (4). Under aerobic conditions most of a 
healthy cell’s energy is derived via oxidative phosphorylation, however 
cancer cells are metabolically reprogrammed for increased glycolysis, the 
so-called Warburg effect (5). While inefficient, increased glycolytic flux 
generates ATP molecules rapidly with glucose used 12 times faster in 
glycolysis versus oxidative phosphorylation (5, 6) providing the energy 
needed for the production of biomolecules and other effector functions (7).  
  
Leukocytes are also reported to undergo the Warburg effect upon activation 
via pathogenic and other stimuli (8-10). As for cancer cells, increased 
glycolysis allows the rapid production of molecules, such as cytokines, 
chemokines, and anti-microbial peptides, and supports processes such as 
migration and phagocytosis (5, 11, 12). This phenomenon is also seen under 
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hypoxic conditions, whereby glucose is converted to lactic acid (11), and 
might explain why monocytes and macrophages exhibit extended hypoxic 
survival (2). Work, mostly from mouse models, has shown that for B and T 
lymphocytes and natural killer (NK) cells, increased glycolytic flux enables 
clonal expansion (13-16) accompanied by the production of pro-
inflammatory cytokines such as IFNγ (14, 16, 17). Glucose dependent 
activation of human monocytes by lipopolysaccharide (LPS) results in a 
switch to heavily glycolytic metabolism supporting the production of 
cytokines (18). This metabolic reprogramming of leukocytes is accompanied 
by elevated production of lactate due to the rapid generation of ATP (9, 18) 
and lactate itself has been reported to have anti-microbial properties (10) 
and a role in IL-17A production (19).  
 
The Bioenergetics Health Index (BHI) has been suggested as a rapidly 
calculated, single value that reflects mitochondrial health (20). BHI takes into 
account beneficial parameters such as maximum respiration and ATP-linked 
respiration whilst incorporating deleterious parameters such as proton leak 
and reduced mitochondrial reserve capacity. Consequently, BHI might offer 
a rapid means of detecting mitochondrial dysfunction allowing early disease 
diagnosis and facilitating precision medicine approaches to disease 
management (20). Monitoring BHI in various clinical settings including cohort 
studies, translational medicine, immunotherapeutics, and even screening of 
drug toxicity might be achieved using peripheral blood mononuclear cells as 
a readily accessible source of patient material. The emerging field of 
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mitochondrial medicine has been demonstrated with techniques such as the 
J-aggregate-forming lipophilic cation 5,5’,6,6’-tetraethyl-
benzimidazolocarbocyanine iodide (JC-1) assay that detects the loss of 
MNC mitochondrial membrane potential, leading to MNC apoptosis among 
HIV positive patients  (21). The diagnostic use of MNC respiratory 
parameters as potential disease biomarkers has been correlated positively 
to a loss of mitochondrial respiratory chain enzymes and function with 
lipoatrophy (22). It has also been suggested that bioenergetic disruption of 
monocytes and macrophages leads to metabolic conditions such as chronic 
kidney disease and atherosclerosis (23, 24). Non-invasive extracellular 
bioflux analysis of cells allows quantification of the ATP-producing 
respiratory processes via measurement of oxygen consumption rate (OCR) 
for oxidative phosphorylation (OP) and extracellular acidification (ECAR) for 
glycolysis. Here we have studied human peripheral blood mononuclear cells 
(MNCs) to not only better understand the bioenergetics profile of these cells 
but as a potential substrate for monitoring BHI. The impact of 
cryopreservation was considered as bulk analysis of cells from different 
donors can be of benefit in settings such as cohort studies; this has been 
shown recently to have a negative impact on BHI (25). To test the utility of 
using MNC BHI in a clinical setting we compared MNCs from pregnant and 
non-pregnant women. While little is known currently about the metabolism of 
haematopoietic cells from pregnant women changes related to insulin 
sensitivity and the handling of glucose by skeletal muscle and adipose tissue 
 7 
are well documented as a normal physiological response from the second 
trimester (26, 27). 
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Materials and Methods 
 
Samples 
Human peripheral blood was collected between 0830 and 1000 from 
healthy, non-fasted individuals into heparinised VacuettesTM (Greiner Bio-
one, Frickenhausen, Germany) and processed within 10 minutes of 
collection. Peripheral blood was also collected from healthy pregnant women 
at > 37 weeks gestation and matched with samples from non-pregnant 
women aged 20-40 years.   All samples were collected with informed written 
consent and ethical approval was obtained from Wales Research Ethics 
Committee 6 (13/WA/0190; 11/WA/0040). 
 
Mononuclear cell isolation 
Mononuclear cells were isolated by layering whole blood (1:1) onto 
Histopaque (Sigma-Aldrich, Poole, UK) prior to centrifugation at 805 x g for 
20 min at room temperature. Mononuclear cells (MNCs) were removed and 
washed with RPMI 1640 (Life Technologies, Paisley, UK) twice by 
centrifugation at 515 x g. The MNC pellet was resuspended in media specific 
for the downstream assay and cell density determined using the Countess® 
automated cell counter (Life Technologies). For the pregnancy part of the 
study red blood cells were removed selectively from both non-pregnant and 
pregnant blood samples using glycophorin A (CD235a) microbeads 
(autoMACS; Miltenyi Biotec, Cologne, Germany) as described by the 
manufacturer. 
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Cryopreservation and resuscitation 
MNCs were cryopreserved and resuscitated using CTL-Cyro™ ABC media 
kit (Cellular Technology Limited) as per manufacturer’s instructions. Briefly, 
cells were cryopreserved by resuspending in CTL-CryoC media and the slow 
addition of an equal volume of solution CryoAB. Cells were then transferred 
to a cryovial and stored at -80°C. Cells were resus citated by thawing in a 
37°C water bath and the slow addition of 5 mL of CT L-thaw solution. 
Resuscitated cells were left for 30 min in RPMI 1640 5% fetal calf serum 
(FCS, HyClone, ThermoFisher Scientific, Massachusetts, USA) and 0.2% 2-
mercaptoethanol (Life Technologies) to reacclimatize. Flow cytometry was 
used to monitor the cellular content of fresh and resuscitated MNCs. 
 
Effect of glycolysis and respiratory inhibitors on cytokine production 
MNCs were cultured at 5 x 105 cells/500 µl of RPMI/5% FCS/0.5 µM 2-ME 
+/- LPS (Ultrapure, 10 ng/mL; InvivoGen, San Diego, USA) at 37°C in 5% 
CO2-in-air for 24 h. Additional treatments included for the 24 h incubation 
were: 2-deoxy-D-glucose (2-DG; 0, 0.5, 1 and 2.5mM; Sigma); rotenone (1, 
2 µM; Seahorse Bioscience), and/or pyruvate (1 mM; Life Technologies). 
After 24 h, cultures were centrifuged at 515 x g for 7 min and cell-free 
supernatants removed and stored at -20oC until analysis of lactate 
dehydrogenase (LDH) and cytokines by ELISAs. 
 
Lactate dehydrogenase cytotoxicity assay 
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Cytotoxicity was measured using a lactate dehydrogenase cytotoxicity assay 
as per manufacturer’s instructions (LDH-Cytotoxicity Assay Kit II; Abcam, 
Cambridge, UK). Briefly, 10 µl culture supernatant was mixed with 100 µl 
LDH reaction mix containing a WST substrate (tetrazolium salt substrate 
with the chemical formula of 4-[3-(4-iodophenyl)-2-(4-nitrophenyl)- 2H-5-
tetrazolio]-1,3-benzene disulfonate sodium salt) and incubated at room 
temperature for 30 min and absorbance at 450nm measured. A positive 
control of lysed cells was used: 5 x 105 cells/100 µl with 10 µl cell lysis 
solution (provided in the kit) at 37°C for 24 h.  
 
Enzyme linked immunosorbent assay 
Analysis of cytokines using ELISA was as per manufacturers’ instruction - 
IFNγ (Ready-Set-Go; eBioscience, San Diego, USA), IL-1β, IL-6 and TNFα 
(DuoSets; R&D Systems). 
 
Bioenergetics analysis 
Adhesion to the bioflux plate 
As the majority of MNCs (the exception being monocytes) are non-adherent, 
Cell-Tak (Corning, Massachusetts, USA) was used at 3.5 µg/cm2 per well 
according to the manufacturer’s instructions to attach them to the XFe24 
bioflux plate (Seahorse Bioscience, Copenhagen, Denmark) used for 
bioenergetics analysis. The potential for Cell-Tak to activate MNCs was 
determined. MNCs were seeded at 2.5 x 105 cells per well with or without 
Cell-Tak and stimulated +/- 10 ng/mL LPS (as before) as a prototypic stimuli 
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of monocytes in particular with IL-6 measured as the output; and CytoStim 
(1/200 from stock; Miltenyi Biotec) or phytohaemagglutinin (PHA, 1 µg/mL; 
Sigma) for 48 h at 37°C as T cell stimuli in partic ular with interferon γ (IFNγ) 
measured as the output. 
 
Oxidative phosphorylation 
Mitochondrial stress is measured via the initial addition of oligomycin to 
block ATP synthase. Then, carbonyl cyanide-p-
trifluoromethoxyphenylhydrazone (FCCP), a proton ionophore that 
selectively removes the regulation of the proton gradient (28), is injected 
allowing the maximum respiration rate to be determined. Finally, rotenone 
and antimycin A inhibit complex I and III, respectively, of the electron 
transport chain.  
 
Cells were resuspended in XF Assay media (Seahorse Bioscience) 
supplemented with 5.5 mM glucose and 1 mM pyruvate as pre-optimised for 
use with the Mito-Stress kit (Seahorse Bioscience). Cells were seeded onto 
a XFe24 bioflux plate (Seahorse Bioscience) at a pre-optimised final 
concentration of 2.5 x 105 cells/80 µl/well and gently centrifuged with no 
brake at 40 x g and the plate then rotated 180o before centrifugation again at 
80 x g to encourage adhesion to the plate and the forming of an evenly 
dispersed monolayer. Cells were then incubated at 37°C for 30 min before 
445 µl pre-warmed XF Assay media was added to each well. Cells were 
returned to the incubator at 37°C for a further 15 min and then processed 
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using the XFe24 Extracellular Flux Analyzer (Seahorse Bioscience). 
Mitochondrial function was measured as OCR after injections of 0.5 µM 
oligomycin (ATP synthase inhibitor), 1 µM FCCP (electron transport chain 
accelerator), and 1 µM antimycin A (complex III inhibitor) plus 1 µM rotenone 
(complex I inhibitor) according to the manufacturer’s instructions.  
 
Glycolysis 
Glycolysis is measured via the initial injection of glucose, the carbohydrate 
precursor of glycolysis. Oligomycin is then added to inhibit ATP synthase as 
above, and finally 2-DG is injected as a competitive inhibitor of glycolysis, 
blocking the enzyme activity of hexokinase thus halting glycolysis.   
 
Cells were resuspended in XF Assay media for use with the glycolysis stress 
kit (Seahorse Bioscience). Cells were attached to the bioflux plates as 
described above and glycolysis was then measured as ECAR after injections 
of differing glucose concentrations (0, 2, 5.5, 11.1 and 25 mM), 0.75 µM 
oligomycin (inhibits ATP synthase forcing the cell to utilize glycolysis only), 
and the competitive inhibitor 2-DG (100 mM).  
  
Total protein estimation 
After completion of the bioenergetics assays, the media was removed and 
the cells washed once with PBS (Life Technologies). Lysis buffer (50 µl, BD 
Biosciences, New Jersey, USA) was then added to each well and the plate 
stored at -20oC for a minimum of 24 h. A bicinchoninic acid (BCA, Sigma) 
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assay on thawed lysates compared to a bovine serum albumin (BSA) protein 
standard (Sigma). Briefly, 10 µl of lysate was mixed with a 50:1 ratio of BCA 
solution to copper II sulfate pentahydrate 4% solution respectively (Sigma) 
and incubated at 37°C for 30 min. The absorbance wa s then measured at 
562 nm. 
 
Data analysis 
OCR and ECAR values were normalized to protein concentrations of 
respective wells with the use of Microsoft Excel version 14.4.4 (Microsoft, 
USA).  
 
The various respiratory parameters were calculated using the following 
methods using data obtained from the Seahorse XFe analyser: 
Mitochondrial stress assay: Non-mitochondrial respiration is the difference 
between the average of the final three measurements after injection of 
antimycin A/rotenone; proton leak is measured as the difference between 
the average of the final three measurements and the averaged three data 
points after oligomycin injection. Removing the non-mitochondrial respiration 
value from the initially averaged three measurements identifies basal 
respiration. ATP-linked respiration was calculated by removing the proton 
leak from the basal respiration value, whereas maximal respiration was 
measured by taking the non-mitochondrial respiration from the averaged 
three data points after FCCP injection. Finally, the reserve respiratory 
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capacity was measured by maximal respiration – basal respiration (Table I) 
(28).  
 
Glycolysis stress assay: An average of the first and last three measurements 
gives a measure of non-glycolytic acidification. After glucose injection the 
averaged three corresponding points were used to calculate basal glycolysis 
after removing the non-glycolytic acidification. Taking the averaged three 
measurements after oligomycin injection and removing the non-glycolytic 
acidification yields glycolytic capacity. Finally the glycolytic reserve was 
calculated by glycolytic capacity – basal glycolysis (Table I). 
 
Flow cytometry 
To monitor T cell subset and monocyte content of fresh and resuscitated 
MNCs 2.5 x 105 cells were incubated with anti-CD3 eFluor®450 (mIgG2a, 
clone OKT3, eBioscience), anti-CD4 AlexaFluor®647 (mIgG2b, clone OKT4, 
eBioscience), anti-CD8 PE (mIgG1, clone HIT8a, eBioscience) and anti-
CD14 eFluor®450 (mIgG1, clone 61D3, eBioscience) antibodies using 
standard techniques. MNC sub-population monitoring of pregnant and non-
pregnant samples was performed as above with the inclusion of anti-CD19 
FITC (mIgG1, clone HIB19, BioLegend, USA).  Cells were acquired  
(FACSAria I, BD Biosciences) and downstream analysis was with Kaluza 
version 1.3, (Beckman Coulter, California, USA).  
 
Statistics 
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Statistical analysis was performed using SPSS version 20 (IBM, USA). Data 
are represented as the mean ± standard error of the mean. The one-sample 
Kolmogorov-Smirnoff test was used to test for normality. Any substantial 
deviation from normality resulted in a non-parametric test being used 
otherwise it was considered appropriate to use parametric statistics. One-
way ANOVA was used to compare the Cell-Tak activation, and 2-deoxy-D-
glucose cytokine output with Bonferroni post hoc tests. Tukey’s post hoc test 
was performed on the metabolic cytokine output data. Paired-samples t-test 
was used for fresh versus resuscitated oxidative phosphorylation data, fresh 
versus resuscitated MNC cytokine outputs, pregnant versus non-pregnant 
oxidative phosphorylation and glycolysis data and flow cytometry cell 
population number data including pregnant versus non-pregnant 
populations. A three-way ANOVA was used for the fresh versus resuscitated 
glycolysis data.  
All experiments have replicate sample sizes of at least n=3 and significant 
values were taken as p < 0.05 graphically denoted as * p ≤ 0.05, ** p ≤ 0.01, 
*** p ≤ 0.001.  
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Results 
 
2-DG down-regulates LPS-mediated cytokine production  
Before detailed investigation of glycolysis and oxidative phosphorylation by 
MNCs, the role of glycolysis in a response by MNCs was determined. LPS 
treatment of MNCs stimulated production of cytokines IL-1β, IL-6 and TNFα 
as expected. The competitive glycolysis inhibitor 2-DG (0, 0.5, 1 & 2.5 mM) 
reduced LPS-mediated cytokine production significantly for all three 
cytokines (Figure 1a).  
 
To explore this further, the cytokine output in the presence of a number of 
treatments, 2-DG, 2-DG + pyruvate (1 mM and 2 mM), pyruvate (1 mM and 
2 mM), rotenone (1 and 2 µM) was measured. The ability of pyruvate to 
bypass the glycolytic step inhibited by 2-DG was considered but had 
negligible effect on the inhibitory effect of 2-DG (Figure 1b). Similarly, 
rotenone (a complex I inhibitor), which inhibits the electron transport chain, 
had no significant effect on cytokine output. Although TNFα levels appeared 
more susceptible to the effects of rotenone this was not significant (Figure 
1b). There was no measureable cell death detected via the LDH assay (data 
not shown).  
 
The effect of Cell-Tak on MNC cytokine outputs 
Bioenergetic analysis using extracellular flux analysis requires an adherent 
cell monolayer so for some cell types, such as lymphocytes, which are 
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typically not adherent, a cell adhesive such as Cell-Tak is required. 
Therefore, the potential of Cell-Tak to activate MNCs was considered. Cell-
Tak and/or gentle centrifugation had no effect on IL-6 or IFNγ levels from 
otherwise unstimulated cells (Figure 2a and b). However, while there was no 
difference in cytostim- or PHA-stimulated IFNγ levels from MNCs irrespective 
of the presence of Cell-Tak or gentle centrifugation (Figure 2a), the 
adherence of MNCs to Cell-Tak was associated with a significant increase in 
LPS-stimulated IL-6 (p = 0.006 versus no Cell-Tak + gentle centrifugation, p 
= 0.003 versus no Cell-Tak/no centrifugation; Figure 2b) but background 
levels in the unstimulated controls remained unaffected.  
 
Bioenergetic profile of mononuclear cells 
To confirm that MNCs gave the expected profile of OCR linked to oxidative 
phosphorylation and ECAR to proton expulsion related to glycolysis a 
preliminary experiment was carried out by first uncoupling the electron 
transport chain with 2,4-DNP (100 µM), then inhibiting glycolysis with 2-DG 
(100 mM) and finally inhibiting complex I via rotenone (2 µM). This resulted 
in an observable and expected change in OCR/ECAR (Figure 3a)(29). 
 
Oxidative phosphorylation and glycolysis were then studied in fresh MNCs 
and matched cryopreserved/resuscitated MNCs (Table II). This was done to 
explore the utility of batch analysis of cryopreserved MNCs as part of cohort 
studies and in other translational medicine settings. The cellular content 
(monocytes and T cell subsets) did not differ significantly between the 
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matched fresh and resuscitated cells (Table III) nor did LPS-stimulated IL-
1β, IL-6 and TNFα (Figure 4). There was no difference in cell death between 
fresh and resuscitated cells cultured with/without LPS for 24 h as measured 
using the LDH assay (data not shown).  
 
For bioenergetics analysis an optimized MNC density of 2.5 x 105 cells/well 
was used. The mitochondrial stress assay injections were also pre-
optimized: oligomycin (0.5 µM), FCCP (1 µM), antimycin A and rotenone 
(both 1 µM). The mitochondrial stress assay gave a typical profile in both 
fresh and resuscitated cells (Figure 4b) but there were significant differences 
in basal respiration (p = 0.021), ATP-linked respiration (p = 0.043 and non-
mitochondrial respiration (p = 0.011) for fresh versus resuscitated; maximum 
respiration was near significant (p = 0.057), but there was no difference in 
reserve respiratory capacity and proton leak. The significant reduction of 
ATP-linked respiration and increase in non-mitochondrial respiration has 
detrimental affects on the BHI of resuscitated cells (2.90 ± 0.71) in 
comparison to fresh (18.28 ± 5.71).  
 
The glycolysis stress assay was carried out with varying concentrations of 
glucose (0, 2, 5.5, 11.1 & 25 mM; Figure 3c and d).  As expected, MNCs 
deprived of glucose (0 mM) had lower glycolytic parameters with the 
exception of glycolysis independent non-glycolytic acidification. Provision of 
increasing concentrations of the substrate, glucose (2, 5.5, 11.1 and 25 mM) 
produced an increase in glycolysis and the glycolytic capacity/reserve for 
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both fresh and resuscitated cells. There was a statistically significant 
difference between fresh and resuscitated cells at different glucose doses (0, 
2, 5.5, 11.1 and 25 mM) for glycolytic reserve (p < 0.001 for both dose and 
conditions), glycolytic capacity (p < 0.001 dose and p = 0.007 for conditions) 
and non-glycolytic acidification (p < 0.001 for both). There was only a 
significant difference for dose for glycolysis (p < 0.001).  
 
Glycolysis and glycolytic capacity levels of MNCs from pregnant 
versus non-pregnant women 
To ensure that differences in cellular composition of MNCs did not differ 
between the two groups and impact on bioenergetics parameters flow 
cytometry was used to monitor major subsets. There was no significant 
difference in any of the major cell populations - monocytes, CD4+ T cells, 
CD8+ T cells, and B cells) – of pregnant versus non-pregnant women (Table 
IV). Mitochondrial function was assessed using the same mitochondrial 
stress injections as above (Figure 5a). There was no significant difference 
between any of the mitochondrial stress respiratory parameters between 
non-pregnant and pregnant MNCs (Table V). The BHI of pregnant MNCs 
was elevated (30.22 ± 5.76 versus 15.66 ± 7.67) but this was not significant.  
The glycolytic stress assay also was applied to the non-pregnant/pregnant 
cohort using a single, physiological concentration of glucose (5.5 mM; Figure 
5b). MNCs from pregnant women had lower basal glycolysis levels (p = 
0.0219) and glycolytic capacity (p = 0.0390; Figure 5c) compared to those 
from non-pregnant women. There was a significant difference between the 
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OCR/ECAR ratio of MNCs from pregnant and non-pregnant women (p = 
0.0207; Figure 5d) suggesting that MNCs from pregnant women rely more 
heavily on OP to obtain their energy whereas those from non-pregnant 
women utilize glucose metabolism, i.e. glycolysis more.   
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Discussion 
Microbial products such as LPS stimulate MNCs to rapidly generate pro-
inflammatory cytokines. Here, we show for the first time the absolute 
requirement for glycolysis for production of IL-1β, IL-6 and TNFα by human 
mononuclear cells. By inhibiting with 2-DG the activity of hexokinase that 
phosphorylates glucose to glucose-6-phosphate to kick start glycolysis, the 
LPS-mediated production of these cytokines was significantly inhibited in a 
dose dependent manner in the absence of measurable cell death. In 
contrast, the complex I respiratory inhibitor rotenone did not significantly 
reduce LPS-stimulated cytokine outputs suggesting that the electron 
transport chain albeit a significant energy producing pathway does not 
contribute directly to the formation of cytokines. These data support the 
hypothesis that the effector function, e.g. cytokine production, of many 
leukocytes is dependent on increased glycolysis as it provides a rapid 
source of ATP to enable a timely immune response (8-10) but is the first to 
show this for human blood mononuclear cells. 
 
Having established a critical role for glycolysis in an effector function of 
MNCs, more detailed analysis of the bioenergetics pathways operational 
within these cells was undertaken. Extracellular flux analysis is a relatively 
new technique for studying the energy-producing pathways utilized by cells. 
As MNCs are mostly non-adherent Cell-Tak was used to generate the 
adherent cell monolayer required for this method. Therefore, the potential 
activating effect of Cell-Tak was considered and it was found that cells 
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adhered to Cell-Tak had a significantly increased LPS-stimulated IL-6 levels. 
This is not due to LPS contamination of the Cell-Tak as Cell-Tak alone did 
not induce IL-6 production by the MNCs so the reasons for this remain 
unknown and are the subject of ongoing investigation.  
 
MNCs used both glycolysis and oxidative phosphorylation pathways. 
Different glucose concentrations were used to provide a more detailed 
analysis of glycolysis. MNCs were deprived of glucose (0 mM), 2 mM was 
used as a minimal addition, 5.5 mM as a widely accepted average 
concentration of circulating glucose under physiological conditions (30), 11.1 
mM as the general cell culture media glucose concentration, and finally 25 
mM was used to provide the MNCs with excess glucose (31); increasing 
glucose concentrations increased the glycolytic capacity of MNCs. 
 
One part of this study was to consider the possibility that cryopreserved 
MNCs could be used to study patient cohorts in a number of clinical and 
translational settings. There were no differences in the cellular content of 
fresh versus cryopreserved/resuscitated cells nor the functional activity of 
these cells as monitored by their ability to respond to LPS for cytokine 
production as reported elsewhere (32, 33). However, bioenergetics profiles 
were impacted by cryopreservation and resuscitation, especially 
mitochondrial function. Cryopreserved/resuscitated MNCs had a three-fold 
increase in non-mitochondrial respiration likely attributable to ROS 
generation and decreased mitochondrial health of the cryopreserved cells 
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(20). Basal respiration and ATP-linked respiration were significantly 
decreased between fresh and cryopreserved/resuscitated cells, again 
providing evidence for damaged mitochondria (25, 34, 35). Glycolysis occurs 
within the cytoplasm and is independent of mitochondrial health. There was 
no significant difference in glycolysis between fresh and 
cryopreserved/resuscitated MNCs hence glycolysis-dependent LPS-
stimulated IL-1β, IL-6 and TNFα production remain unaffected. However, 
there was a significant difference between the glycolytic capacity, glycolytic 
reserve and non-glycolytic acidification, all indicating reduced bioenergetic 
health. Thus the cryopreservation and resuscitation of MNCs has a 
detrimental effect on the bioenergetic health of the cells due to the damaging 
effect on the mitochondria, the main energy source of the cells. The 
detrimental impact of cryopreservation on MNC BHI has also been 
demonstrated recently by another group (25). While a recovery period after 
resuscitation might prove beneficial the impact on the cellular profile then 
used for bioenergetics analysis (e.g. monocytes lost due to adherence to cell 
culture plastics during recovery phase) led us to decide not to pursue this 
approach.  
 
To test the translational utility of MNC BHI and bioenergetics profiling in 
general we applied the technique to MNCs from full term pregnant and age 
matched non-pregnant women. It is well documented that insulin sensitivity 
of adipose tissue and skeletal muscle of pregnant women changes from the 
second trimester to favour passage of glucose across the placenta for use 
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by the fetus (36). The impact of this on haematopoietic cells and thereby 
immune function has not been considered although there are numerous 
studies reporting differences in for example cytokine production with 
pregnancy (37-39).  Here we show that while there were no significant 
difference between any of the OP parameters, basal glycolysis and glycolytic 
capacity were significantly reduced In MNCs from pregnant women. 
Consequently, the OCR/ECAR ratio between the two groups differed 
significantly and while BHI increased with pregnancy this was not significant. 
MNCs from pregnant women are therefore more likely to utilise OP for their 
energy demands rather than glycolysis as in non-pregnant women and might 
fuel their energy needs through other substrates, such as fatty acids that 
feed into OP (36). These findings provide preliminary data that, like skeletal 
muscle and adipose tissue, blood mononuclear cells in pregnancy down-
regulate their use of glucose perhaps via decreased expression of pyruvate 
kinase (40) but this is now the focus of ongoing work.  
 
The study of heterogeneous MNCs might lend itself to comparing the 
bioenergetics health index in clinical and translational settings but does little 
to improve our understanding of how discrete leukocyte populations differ in 
their energy requirements in the resting and activated states. Further work 
with isolated individual leukocyte populations will provide further insight into 
specific metabolic function of human immune cells. The bioenergetic profiles 
of isolated human monocytes, neutrophils and T cells have recently been 
identified revealing distinct differences between glycolysis and oxidative 
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phosphorylation rates for each populations postulated to reflect their 
biological roles (41). 
 
 
While the study of mixed populations as here has its limitations such an 
approach might provide rapid turnaround of valuable bioenergetic 
information without the use of expensive single population separation 
techniques as demonstrated here by comparing MNCs from pregnant and 
non-pregnant women. MNCs from septic shock patients have reduced 
oxygen consumption and ATP synthesis (42), and extracellular flux analysis 
measured by high-resolution respiratory analyses could quickly determine 
this from small volumes of blood that would reflect the broad health status of 
the patient. This bioenergetic information has a potential role in identifying 
mitochondrial abnormalities, defining the revolutionary concept of 
Bioenergetic Health Index (BHI) (20). BHI could identify mitochondrial 
dysfunction that presents itself as increased non-mitochondrial respiration, 
increased proton leak and lower reserve capacity, suggesting that the 
mitochondria are damaged and unhealthy. Early identification could predict a 
patient’s susceptibility to particular syndromes (20) and identification and 
monitoring of these stress parameters within metabolic disorders such as 
diabetes could facilitate precision medicine. 
  
 26
Acknowledgments  
This work was supported by an Academic Expertise for Business (A4B) 
grant and a Life Sciences Research Network Wales Platform Grant. We 
thank the staff at the Joint Clinical Research Facility, and all blood donors 
who generously donated their blood towards this research.  
 27
References 
 
1. Pearce EL, Pearce EJ. Metabolic pathways in immune cell activation 
and quiescence. Immunity. 2013;38(4):633-43. 
2. Roiniotis J, Dinh H, Masendycz P, Turner A, Elsegood CL, Scholz 
GM, Hamilton JA. Hypoxia prolongs monocyte/macrophage survival and 
enhanced glycolysis is associated with their maturation under aerobic 
conditions. Journal of immunology. 2009;182(12):7974-81. 
3. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the 
Warburg effect: the metabolic requirements of cell proliferation. Science. 
2009;324(5930):1029-33. 
4. Turner N, Cooney GJ, Kraegen EW, Bruce CR. Fatty acid 
metabolism, energy expenditure and insulin resistance in muscle. The 
Journal of endocrinology. 2014;220(2):T61-79. 
5. Palsson-McDermott EM, O'Neill LA. The Warburg effect then and 
now: from cancer to inflammatory diseases. BioEssays : news and reviews 
in molecular, cellular and developmental biology. 2013;35(11):965-73. 
6. Macintyre AN, Rathmell JC. Activated lymphocytes as a metabolic 
model for carcinogenesis. Cancer & metabolism. 2013;1(1):5. 
7. Suchorolski MT, Paulson TG, Sanchez CA, Hockenbery D, Reid BJ. 
Warburg and Crabtree effects in premalignant Barrett's esophagus cell lines 
with active mitochondria. PloS one. 2013;8(2):e56884. 
8. Marsin AS, Bouzin C, Bertrand L, Hue L. The stimulation of glycolysis 
by hypoxia in activated monocytes is mediated by AMP-activated protein 
 28
kinase and inducible 6-phosphofructo-2-kinase. The Journal of biological 
chemistry. 2002;277(34):30778-83. 
9. Wahl DR, Byersdorfer CA, Ferrara JL, Opipari AW, Jr., Glick GD. 
Distinct metabolic programs in activated T cells: opportunities for selective 
immunomodulation. Immunological reviews. 2012;249(1):104-15. 
10. Yang E, Fan L, Jiang Y, Doucette C, Fillmore S. Antimicrobial activity 
of bacteriocin-producing lactic acid bacteria isolated from cheeses and 
yogurts. AMB Express. 2012;2(1):48. 
11. Fangradt M, Hahne M, Gaber T, Strehl C, Rauch R, Hoff P, Lohning 
M, Burmester GR, Buttgereit F. Human monocytes and macrophages differ 
in their mechanisms of adaptation to hypoxia. Arthritis research & therapy. 
2012;14(4):R181. 
12. Freemerman AJ, Johnson AR, Sacks GN, Milner JJ, Kirk EL, Troester 
MA, Macintyre AN, Goraksha-Hicks P, Rathmell JC, Makowski L. Metabolic 
reprogramming of macrophages: glucose transporter (GLUT1)-mediated 
glucose metabolism drives a pro- inflammatory phenotype. The Journal of 
biological chemistry. 2014. 
13. Doughty CA, Bleiman BF, Wagner DJ, Dufort FJ, Mataraza JM, 
Roberts MF, Chiles TC. Antigen receptor-mediated changes in glucose 
metabolism in B lymphocytes: role of phosphatidylinositol 3-kinase signaling 
in the glycolytic control of growth. Blood. 2006;107(11):4458-65. 
14. Kramer PA, Ravi S, Chacko B, Johnson MS, Darley-Usmar VM. A 
review of the mitochondrial and glycolytic metabolism in human platelets and 
 29
leukocytes: Implications for their use as bioenergetic biomarkers. Redox 
biology. 2014;2:206-10. 
15. Cao MD, Sitter B, Bathen TF, Bofin A, Lonning PE, Lundgren S, 
Gribbestad IS. Predicting long-term survival and treatment response in 
breast cancer patients receiving neoadjuvant chemotherapy by MR 
metabolic profiling. NMR in biomedicine. 2012;25(2):369-78. 
16. Keppel MP, Saucier N, Mah AY, Vogel TP, Cooper MA. Activation-
Specific Metabolic Requirements for NK Cell IFN-gamma Production. 
Journal of immunology. 2015;194(4):1954-62. 
17. Lund FE. Cytokine-producing B lymphocytes-key regulators of 
immunity. Current opinion in immunology. 2008;20(3):332-8. 
18. Dietl K, Renner K, Dettmer K, Timischl B, Eberhart K, Dorn C, 
Hellerbrand C, Kastenberger M, Kunz-Schughart LA, Oefner PJ, Andreesen 
R, Gottfried E, Kreutz MP. Lactic acid and acidification inhibit TNF secretion 
and glycolysis of human monocytes. Journal of immunology. 
2010;184(3):1200-9. 
19. Yabu M, Shime H, Hara H, Saito T, Matsumoto M, Seya T, Akazawa 
T, Inoue N. IL-23-dependent and -independent enhancement pathways of 
IL-17A production by lactic acid. International immunology. 2011;23(1):29-
41. 
20. Chacko BK, Kramer PA, Ravi S, Benavides GA, Mitchell T, Dranka 
BP, Ferrick D, Singal AK, Ballinger SW, Bailey SM, Hardy RW, Zhang J, Zhi 
D, Darley-Usmar VM. The Bioenergetic Health Index: a new concept in 
mitochondrial translational research. Clinical science. 2014;127(6):367-73. 
 30
21. Sternfeld T, Tischleder A, Schuster M, Bogner JR. Mitochondrial 
membrane potential and apoptosis of blood mononuclear cells in untreated 
HIV-1 infected patients. HIV medicine. 2009;10(8):512-9. 
22. Shikuma CM, Gerschenson M, Chow D, Libutti DE, Willis JH, Murray 
J, Capaldi RA, Marusich M. Mitochondrial oxidative phosphorylation protein 
levels in peripheral blood mononuclear cells correlate with levels in 
subcutaneous adipose tissue within samples differing by HIV and lipoatrophy 
status. AIDS research and human retroviruses. 2008;24(10):1255-62. 
23. Ravi S, Mitchell T, Kramer PA, Chacko B, Darley-Usmar VM. 
Mitochondria in monocytes and macrophages-implications for translational 
and basic research. The international journal of biochemistry & cell biology. 
2014;53:202-7. 
24. Pandzic Jaksic V, Gizdic B, Miletic Z, Ostovic KT, Jaksic O. 
Monocytes in metabolic disorders--opportunities for flow cytometry 
contributions. Collegium antropologicum. 2010;34(1):319-25. 
25. Keane KN, Calton EK, Cruzat VF, Soares MJ, Newsholme P. The 
Impact of Cryopreservation on Human Peripheral Blood Leukocyte 
Bioenergetics. Clinical science. 2015. 
26. Friedman JE, Kirwan JP, Jing M, Presley L, Catalano PM. Increased 
skeletal muscle tumor necrosis factor-alpha and impaired insulin signaling 
persist in obese women with gestational diabetes mellitus 1 year 
postpartum. Diabetes. 2008;57(3):606-13. 
27. Ong KK, Diderholm B, Salzano G, Wingate D, Hughes IA, 
MacDougall J, Acerini CL, Dunger DB. Pregnancy insulin, glucose, and BMI 
 31
contribute to birth outcomes in nondiabetic mothers. Diabetes care. 
2008;31(11):2193-7. 
28. Hill BG, Benavides GA, Lancaster JR, Jr., Ballinger S, Dell'Italia L, 
Jianhua Z, Darley-Usmar VM. Integration of cellular bioenergetics with 
mitochondrial quality control and autophagy. Biological chemistry. 
2012;393(12):1485-512. 
29. Wu M, Neilson A, Swift AL, Moran R, Tamagnine J, Parslow D, 
Armistead S, Lemire K, Orrell J, Teich J, Chomicz S, Ferrick DA. 
Multiparameter metabolic analysis reveals a close link between attenuated 
mitochondrial bioenergetic function and enhanced glycolysis dependency in 
human tumor cells. American journal of physiology Cell physiology. 
2007;292(1):C125-36. 
30. Kolodziejek AM, Caplan AB, Bohach GA, Paszczynski AJ, Minnich 
SA, Hovde CJ. Physiological levels of glucose induce membrane vesicle 
secretion and affect the lipid and protein composition of Yersinia pestis cell 
surfaces. Applied and environmental microbiology. 2013;79(14):4509-14. 
31. Lin Y, Berg AH, Iyengar P, Lam TK, Giacca A, Combs TP, Rajala 
MW, Du X, Rollman B, Li W, Hawkins M, Barzilai N, Rhodes CJ, Fantus IG, 
Brownlee M, Scherer PE. The hyperglycemia-induced inflammatory 
response in adipocytes: the role of reactive oxygen species. The Journal of 
biological chemistry. 2005;280(6):4617-26. 
32. Wang SY, Hsu ML, Tzeng CH, Hsu HC, Ho CK. The influence of 
cryopreservation on cytokine production by human T lymphocytes. 
Cryobiology. 1998;37(1):22-9. 
 32
33. Kreher CR, Dittrich MT, Guerkov R, Boehm BO, Tary-Lehmann M. 
CD4+ and CD8+ cells in cryopreserved human PBMC maintain full 
functionality in cytokine ELISPOT assays. Journal of immunological 
methods. 2003;278(1-2):79-93. 
34. Larsen S, Wright-Paradis C, Gnaiger E, Helge JW, Boushel R. 
Cryopreservation of human skeletal muscle impairs mitochondrial function. 
Cryo letters. 2012;33(3):170-6. 
35. O'Connell M, McClure N, Lewis SE. The effects of cryopreservation 
on sperm morphology, motility and mitochondrial function. Human 
reproduction. 2002;17(3):704-9. 
36. Herrera E. Lipid metabolism in pregnancy and its consequences in 
the fetus and newborn. Endocrine. 2002;19(1):43-55. 
37. Vanders RL, Gibson PG, Wark PA, Murphy VE. Alterations in 
inflammatory, antiviral and regulatory cytokine responses in peripheral blood 
mononuclear cells from pregnant women with asthma. Respirology. 
2013;18(5):827-33. 
38. Breckler LA, Hale J, Taylor A, Dunstan JA, Thornton CA, Prescott SL. 
Pregnancy IFN-gamma responses to foetal alloantigens are altered by 
maternal allergy and gravidity status. Allergy. 2008;63(11):1473-80. 
39. Sakai M, Tsuda H, Tanebe K, Sasaki Y, Saito S. Interleukin-12 
secretion by peripheral blood mononuclear cells is decreased in normal 
pregnant subjects and increased in preeclamptic patients. American journal 
of reproductive immunology. 2002;47(2):91-7. 
 33
40. Xu Y, Madsen-Bouterse SA, Romero R, Hassan S, Mittal P, Elfline M, 
Zhu A, Petty HR. Leukocyte pyruvate kinase expression is reduced in 
normal human pregnancy but not in pre-eclampsia. American journal of 
reproductive immunology. 2010;64(2):137-51. 
41. Chacko BK, Kramer PA, Ravi S, Johnson MS, Hardy RW, Ballinger 
SW, Darley-Usmar VM. Methods for defining distinct bioenergetic profiles in 
platelets, lymphocytes, monocytes, and neutrophils, and the oxidative burst 
from human blood. Laboratory investigation; a journal of technical methods 
and pathology. 2013;93(6):690-700. 
42. Japiassu AM, Santiago AP, d'Avila JC, Garcia-Souza LF, Galina A, 
Castro Faria-Neto HC, Bozza FA, Oliveira MF. Bioenergetic failure of human 
peripheral blood monocytes in patients with septic shock is mediated by 
reduced F1Fo adenosine-5'-triphosphate synthase activity. Critical care 
medicine. 2011;39(5):1056-63. 
 
 
 
 
 
 
 
 34
Figures legends 
Figure 1. The effect of inhibitors of glycolysis and oxidative phosphorylation 
on lipopolysaccharide (LPS)-mediated cytokine outputs of human peripheral 
blood mononuclear cells (MNCs). (a) IL-1β, IL-6 and TNFα after stimulation 
+/- LPS (10 ng/mL) for 24 h in the presence of varying concentrations of 2-
deoxy-D-glucose (2-DG, 0-2.5 mM). Data represented as percentage of the 
LPS control. Statistical significance compared to LPS was evaluated using 
one-way ANOVA with Bonferroni post hoc test (n = 5; * p ≤ 0.05, ** p ≤ 0.01, 
*** p ≤ 0.001). Significance also observed (not shown on graph) regarding 
cytokine IL-6 production treated with 0.5 mM 2-DG/LPS compared to both 1 
and 2.5 mM 2-DG/LPS (b) Cytokine output (IL-1β, IL-6 and TNFα) after 
stimulation +/- LPS for 24 h in the presence of various respiratory inhibitors 
or substrates (pyruvate; 1 + 2 mM, 2-DG; 2.5 mM and rotenone; 1 + 2 µM). 
Data are shown as pg/mL ± SEM. Statistical significance compared to LPS 
was evaluated using one-way ANOVA with Tukey post hoc test (n = 4; * p ≤ 
0.05, ** p ≤ 0.01, *** p ≤ 0.001). 
 
Figure 2. The effect of Cell-Tak and gentle centrifugation on cytokine 
production by MNCs. (a) LPS-stimulated IL-6 levels (pg/mL ± SEM, n = 3) 
after 24 h incubation, and (b) Cytostim- and PHA-stimulated IFNγ levels 
(pg/mL ± SEM, n = 3) after 48 h incubation from cells +/- Cell-Tak with or 
without gentle centrifugation (spin).  Statistical significance was measured 
using a one-way ANOVA ** p ≤ 0.01. 
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Figure 3. The bioenergetics profile of MNCs. (a) Combinatory metabolic 
profile of fresh MNCs with injections 2,4-dinitrophenol (2,4-DNP, 100 µM), 2-
DG (100 mM) and rotenone (2 µM), showing both oxygen consumption rate 
(OCR) and extracellular acidification rate (ECAR) values (n=4). (b) 
Mitochondrial stress profile of matched fresh and cryopreserved/resuscitated 
MNCs with injections oligomycin (0.75 µM), carbonyl cyanide-4-
(trifluoromethoxy)phenylhydrazone (FCCP; 1 µM) and antimycin A/rotenone 
(both 1 µM). (c) Fresh and (d) cryopreserved mononuclear cell glycolytic 
stress profile with differing concentrations of glucose (0, 2, 5.5, 11.1 and 25 
mM) along with oligomycin (0.75 µM) and 2-DG (100 mM). (e) Comparative 
glycolytic parameters of matched fresh versus cryopreserved/resuscitated 
MNCs. All data are normalized to µg protein and shown as mean ± SEM 
(n=4). Statistical differences are reported in the text. 
 
Figure 4. Cytokine response by matched fresh versus 
cryopreserved/resuscitated MNCs. Comparative concentrations of IL-1β, IL-
6 and TNFα from fresh and cryopreserved MNCs after treatment +/- LPS (10 
ng/mL) for 24 h. Data are shown as pg/mL ± SEM (n = 7). 
 
Figure 5. Bioenergetic profile of MNCs from non-pregnant versus pregnant 
women. MNCs from non-pregnant and pregnant donors were compared for 
(a) Mitochondrial stress profile with injections oligomycin (0.75 µM), FCCP (1 
µM) and antimycin A/rotenone (both 1 µM); (b) Glycolytic stress profile with 
injections of glucose (5.5mM), oligomycin (0.75 µM) and 2-DG (100 mM). (c) 
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Comparative glycolytic respiratory parameters, and (d) OCR/ECAR ratio of 
MNCs from non-pregnant and pregnant women. All data are normalized to 
µg protein and shown as mean ± SEM (n=7). Statistical differences are 
reported in the text, * p ≤ 0.05. 
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Figure 2 
(a) 
 
 
 
 
 
 
 
 
 
 41
(b) 
 
 
0 
5000 
10000 
15000 
20000 
25000 
30000 
35000 
40000 
45000 
50000 
+ - - 
+ + - 
IF
N
γ     
p
g
/m
L     
(±
S
E
M
)     
Uns mulated 
CytoS m 
PHA 
Cell-Tak 
 
Spin 
 42
Figure 3 
(a) 
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(b) 
 
 (c) 
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(d) 
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Figure 4  
 
 
 
 
 
0 
200 
400 
600 
800 
1000 
1200 
Fresh Cryo 
IL
-1
β
        
(p
g
/m
L)
    
Uns mulated 
LPS 
0 
1000 
2000 
3000 
4000 
5000 
6000 
7000 
8000 
9000 
10000 
Fresh Cryo 
IL
-6
    (
p
g
/m
L)
    
Uns mulated 
LPS 
0 
50 
100 
150 
200 
250 
300 
350 
Fresh Cryo 
T
N
F
-α
    (
p
g
/m
L)
    
Uns mulated 
LPS 
 46
Figure 5 
(a) 
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(c) 
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Table I. Various respiratory parameters calculated using the bioenergetic 
profiles produced by the Seahorse XF analyzer. 
 
Parameter Calculation* 
Proton leak Difference between last three and oligomycin 
injection measurements 
Non-mitochondrial 
respiration 
Measurement after antimycin A/rotenone 
Basal respiration Initial three measurements – non-mitochondrial 
respiration 
ATP-linked respiration Basal respiration – proton leak 
Maximal respiration Difference between FCCP and antimycin 
A/rotenone injections 
Reserve respiratory 
capacity 
Basal respiration – maximal respiration 
Glycolysis 
Glucose injection – non-glycolytic acidification 
Glycolytic capacity Oligomycin injection – non-glycolytic 
acidification 
Glycolytic reserve Glycolytic capacity - glycolysis 
Non-glycolytic acidification Averaged first and last triplicate measurements 
* All triplicate measurements are averaged. 
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Table II. Comparative oxidative phosphorylation parameters of matched 
fresh versus cryopreserved/resuscitated MNCs. 
 
 
Respiratory Parameter 
Fresh OCR (± 
SEM; 
pmoles/min/µg 
protein) 
Cryopreserved 
OCR (± SEM; 
pmoles/min/µg 
protein) 
p-
value 
Basal respiration 7.71 (± 0.35) 5.50 (± 0.31) 0.021 
ATP-linked respiration 7.23 (± 0.31) 5.15 (± 0.38) 0.043 
Non-mitochondrial 
respiration 
3.31 (± 0.18) 9.73 (± 1.06) 0.011 
Maximal respiration 11.23 (± 0.76) 8.19 (± 0.29) 0.057 
Reserve respiratory 
capacity 
3.52 (± 0.66) 2.69 (± 0.23) 0.306 
Proton leak 0.47 (± 0.08) 0.35 (± 0.14) 0.437 
BHI 18.28 (± 5.71)  2.90 (± 0.71) 0.785 
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Table III. Percentage of CD14+ monocytes, CD3+ T cells, and the main T 
cell subsets (CD3+/CD4+ and CD3+/CD8+) as a percentage of total CD3+ T 
cells in freshly isolated and resuscitated MNC preparations. The CD4:CD8 
ratio is also shown (n = 7). 
 
Cell 
Population 
Fresh ± SEM 
(%) 
Resuscitated ± SEM 
(%) 
p-value 
CD14+ 12.59 (± 1.52) 16.66 (± 1.69) 0.083 
CD3+ 64.92 (± 2.05) 71.02 (± 2.35) 0.100 
CD3+ CD4+ 64.78 (± 2.84) 63.71 (± 2.97) 0.821 
CD3+ CD8+ 24.07 (± 2.06) 24.39 (± 2.62) 0.939 
CD4+: CD8+ 
ratio 
2.69 (± 0.34) 2.61 (± 0.47) 0.950 
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Table IV. Percentage of CD14+ monocytes, CD19+ B cells, CD3+ T cells, 
and the main T cell subsets (CD3+/CD4+ and CD3+/CD8+) as a percentage 
of total CD3+ T cells in MNCs from non-pregnant and pregnant women. The 
CD4:CD8 ratio is also shown (n = 7/group). 
 
Cell 
Population 
Non-pregnant ± 
SEM (%) 
Pregnant ± SEM (%) p-value 
CD14+ 12.18 (± 2.65) 11.49 (± 2.19) 0.8114 
CD19+ 5.26 (± 0.80) 4.97 (± 0.69) 0.7425 
CD3+ 69.39 (± 3.61) 71.76 (± 3.21) 0.5613 
CD3+ CD4+ 54.55 (± 1.55) 51.9 (± 2.68) 0.3054 
CD3+ CD8+ 25.34 (± 2.08) 26.2 (± 1.69) 0.7029 
CD4+: CD8+ 
ratio 
1.59 (± 0.24) 2.04 (± 0.22) 0.1161 
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Table V. Comparative oxidative phosphorylation parameters of MNCs from 
non-pregnant versus pregnant women. 
 
Respiratory Parameter 
Non-Pregnant 
OCR (± SEM; 
pmoles/min/µg 
protein) 
Pregnant  
OCR (± SEM; 
pmoles/min/µg 
protein) 
p-
value 
Basal respiration 6.28 (± 0.54) 5.71 (± 0.52) 0.4639 
ATP-linked respiration 3.29 (± 0.78) 3.88 (± 0.48) 0.5319 
Non-mitochondrial 
respiration 
2.44 (± 0.41) 1.23 (± 0.39) 0.0531 
Maximal respiration 11.62 (± 1.28) 12.22 (± 1.36) 0.7559 
Reserve respiratory 
capacity 
5.34 (± 1.00) 6.50 (± 1.01) 0.4269 
Proton leak 0.78 (± 0.19) 0.60 (± 0.18) 0.3759 
BHI 15.66 (± 7.67)  30.22 (± 5.76) 0.1551 
 
